LYRA
Lyra Therapeutics Inc.
$5.76
+$0.24(+4.35%)
28
Overall
40
Value
16
Tech
--
Quality
Market Cap
$9.77M
Volume
13.66K
52W Range
$3.81 - $37.50
Target Price
$11.50
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | $285.0K | $1.4M | $1.6M | $1.5M | ||
| Total Revenue | -- | $285.0K | $1.4M | $1.6M | $1.5M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | $285.0K | $1.4M | $1.6M | $1.5M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $22.2M | $43.9M | $56.4M | $68.7M | $97.9M | ||
| Research & Development | $12.5M | $29.7M | $38.8M | $48.0M | $43.8M | ||
| Research Expense | $12.5M | $29.7M | $38.8M | $48.0M | $43.8M | ||
| Selling, General & Administrative | $9.7M | $14.2M | $17.6M | $19.1M | $18.5M | ||
| General & Administrative Expenses | $9.7M | $14.2M | $17.6M | $19.1M | $18.5M | ||
| Salaries & Wages | -- | -- | -- | $5.9M | -- | ||
| Depreciation & Amortization | $100.0K | $1.0M | $1.1M | $278.0K | $471.0K | ||
| Depreciation & Amortization | $100.0K | $1.0M | $1.1M | $278.0K | -- | ||
| Other Operating Expenses | $1.8M | $5.6M | $5.0M | $68.7M | $97.9M | ||
| OPERATING INCOME | |||||||
| Operating income | $-22.2M | $-43.6M | $-56.3M | $-67.1M | $-96.3M | ||
| EBITDA | $-22.1M | $-42.6M | $-53.9M | $-62.4M | $-92.9M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $82.0K | $102.0K | $1.0M | $4.5M | $3.0M | ||
| Net Non-Operating Interest Income/Expense | $82.0K | $102.0K | $1.0M | $4.5M | $3.0M | ||
| Other Income/Expense | -- | -- | $-1.3M | $1.6M | $1.9M | ||
| Other Special Charges | -- | -- | -- | $4.5M | $3.0M | ||
| SPECIAL ITEMS | |||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $10.9M | ||
| Special Income Charges | -- | -- | -- | $-1.6M | $-10.9M | ||
| Impairment of Capital Assets | -- | -- | -- | $1.6M | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-22.2M | $-43.6M | $-55.0M | $-62.6M | $-93.4M | ||
| Pre-Tax Income | $-22.1M | $-43.5M | $-55.3M | $-62.6M | $-93.4M | ||
| INCOME TAX | |||||||
| Tax Provision | -- | -- | $13.0K | $59.0K | $39.0K | ||
| NET INCOME | |||||||
| Net Income | $-22.1M | $-43.5M | $-55.3M | $-62.7M | $-93.4M | ||
| Net Income (Continuing Operations) | $-22.1M | $-43.5M | $-55.3M | $-62.7M | $-93.4M | ||
| Net Income (Discontinued Operations) | $-22.1M | $-43.5M | $-55.3M | $-62.7M | $-93.4M | ||
| Net Income (Common Stockholders) | $-22.2M | $-43.5M | $-55.3M | $-62.7M | $-93.4M | ||
| Normalized Income | -- | $-34.4M | -- | -- | -- | ||
| TOTALS | |||||||
| Total Expenses | $22.2M | $43.9M | $56.4M | $68.7M | $97.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $171.8K | $259.7K | $604.7K | $996.1K | $65.1M | ||
| Average Shares Outstanding (Diluted) | $171.8K | -- | $604.7K | $996.1K | $65.1M | ||
| Shares Outstanding | $259.0K | $260.2K | $636.6K | $1.2M | $65.9M | ||
| Basic EPS | $-129.5 | $-167.5 | $-91.5 | $-63 | $-1.43 | ||
| Basic EPS (Continuing Operations) | $-129.5 | $-167.5 | $-91.5 | $-63 | $-1.43 | ||
| Diluted EPS | $-129.5 | $-167.5 | $-91.5 | $-63 | $-1.43 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-91.5 | $-63 | $-1.43 | ||
| OTHER METRICS | |||||||
| Accretion On Preferred Stock | $115.0K | -- | -- | -- | -- | ||
| Other Gand A | $9.7M | $14.2M | $17.6M | $19.1M | $18.5M | ||
| Other Impairment Of Capital Assets | -- | -- | $1.3M | $1.6M | $1.9M | ||
| Otherunder Preferred Stock Dividend | $115.0K | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $115.0K | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | $10.9M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LYRA | $5.76 | +4.3% | 13.66K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |